Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo,...
$BFRI - taking off 1200 percent upside potential The chart looks excellent
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy...
Looking Long, seeking bullish PA around buy zone. Looking to execute on a share dealing account, stop loss is kept in mind.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics.
BFRI Biofrontera is a biopharmaceutical company which commercializes pharmaceutical products for the treatment of dermatological conditions in the U.S. Benchmark brokerage Initiated Coverage on BFRI with a Buy rating and a price of $11.00 Roth Capital brokerage Initiated Coverage on BFRI with a Buy rating and a price of $20.00 Looking forward to read your...
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy...
High short interest according to S3: $BFRI – SI 83% Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic...
Biofrontera Inc., BFRI, is a biopharmaceutical company that develops and provides dermatological products for the treatment of skin diseases in the US. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red...
Low float was actively runner few days ago with potential long position. what do you think ?
Wow! I hope some of you caught this rocket. Broke the beautiful ascending triangle for a huge move. Tune in for more bangers guys.
BFRI forming an Ascending Triangle on this 45 minute chart. With volume, this should easily explode over 8, keep on eye out for this one.
According to MarketWatch, 89.54% of the float of Biofrontera Inc. (BFRI) is shorted. Are you ready for a short squeeze? How high will it go?
Note: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States....
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red...